How is Our Research Funded?
As a 501(c)(3) non-profit corporation, many of NFFRE's funds come from various industry and government sponsors. These industry sponsors and government agencies sponsor specific studies they want done or provide us with grants. Some of our most prominent sponsors are Sanofi, Novartis, AstraZeneca, Boston Scientific, Kowa Research Institute, Cirius Therapeutics, Phillips Respironics, The National Heart, Lung, and Blood Institute (NHLBI), The Department of Defense, The Department of Veterans Affairs, The National Institute of Health (NIH), The Department of Aids, The Institutional Review Board (IRB), and The University of Florida.
Peruvemba S Sriram, MD
CHRONICLE (A Longitudinal Prospective Observational Study of the Characteristics, Treatment Patterns and Health Outcomes of Individuals with Severe Asthma in the United States)
PI: Peruvemba S Sriram
The CHRONICLE Study will provide a contemporary description of the epidemiology and medical management of US adults with severe asthma who have not achieved control with high-dose ICS therapy and additional controllers. Additionally, the study will describe the use of and outcomes associated with recently approved monoclonal antibody therapies for severe asthma. The primary objective of the CHRONICLE Study is to describe patient characteristics, treatment patterns, and health outcomes among a large, geographically diverse cohort of US adults with severe asthma who are not controlled on high-dose ICS with additional controllers and/or require chronic systemic corticosteroid or monoclonal antibody therapy.
Michael Bubb, MD
ASLeap (A Randomized, Double-blind, Parallel-group, Multicenter Study of Secukinumab to Compare 300 mg and 150 mg at Week 52 in Patients With Ankylosing Spondylitis Who Are Randomized to Dose Escalation After Not Achieving Inactive Disease During an Initial 16 Weeks of Open-label Treatment With Secukinumab 150 mg)
PI: Michael Bubb
This is a randomized, double-blind, parallel-group, multicenter study of secukinumab. The purpose of this study is to estimate the difference in clinical response between 300 mg and 150 mg of secukinumab at Week 52, which follows randomization to dose escalation at Week 16 for patients with Ankylosing Spondylitis who inadequately respond to open-label secukinumab 150 mg. This study will also investigate the association between treatment andsleep disturbances, as well as daytime activity patterns.